Reactivity against the epitope region 4 (ER 4) on the DNA topoisomerase I molecule as a new predictor for progressive restrictive pulmonary function abnormality in patients with systemic sclerosis

Junichi Kaburaki, Masataka Kuwana, Yasuo Ikeda, Michito Hirakata, Yutaka Okano, Takeshi Tojo

Research output: Contribution to journalArticle

Abstract

Our previous studies showed that serum anti-DNA topoisomerase I (topo I) antibody is associated with pulmonary interstitial fibrosis and restrictive pulmonary function abnormality in patients with systemic sclerosis (SSc). We also demonstrated that at least four epitopes exist on the topo I molecule, and a region from amino acid residues 658-700 of the topo I molecule is referred to as epitope region 4 (ER 4). In this study, we examined the reactivity against ER 4 in sera from 28 anti-topo I antibody positive patients with SSc by immunoblotting. We then clarified the clinical significance of this reactivity against ER 4 in terms of the progressive restrictive pulmonary function abnormality. The reactivity against ER 4 was found to be positive in 15 patients (ER 4 +) and negative in 13 patients (ER 4 —). Differences in gender, mean age at onset, and mean observation period were not significant among these groups. Restrictive pulmonary function abnormality defined as results of percent vital capacity (%VC) less than 80% was found in 12 ER 4+patients and 8 ER 4-patients, although this difference was not significant. However, when progressive restrictive pulmonary function abnormality is defined as both %VC less than 80% and 10% reduction during their observation period, this abnormality was found exclusively in 9 ER 4 + patients. This difference was significant (p < 0.01). Moreover, this progressive abnormality was found in spite of therapy such as prednisolone and D-penicillamine. These results indicated that the reactivity against ER 4 is a useful predictor for the progressive restrictive pulmonary function abnormality in patients with SSc.

Original languageEnglish
Pages (from-to)547-551
Number of pages5
JournalJapanese Journal of Clinical Immunology
Volume17
Issue number5
DOIs
Publication statusPublished - 1994

Fingerprint

Type I DNA Topoisomerase
Systemic Scleroderma
Epitopes
Lung
Observation
Penicillamine
Antibodies
Pulmonary Fibrosis
Vital Capacity
Prednisolone
Serum
Age of Onset
Immunoblotting

Keywords

  • anti-DNA topoisomerase I antibody
  • epitope
  • restrictive pulmonary function abnormality
  • scleroderma
  • systemic sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Reactivity against the epitope region 4 (ER 4) on the DNA topoisomerase I molecule as a new predictor for progressive restrictive pulmonary function abnormality in patients with systemic sclerosis. / Kaburaki, Junichi; Kuwana, Masataka; Ikeda, Yasuo; Hirakata, Michito; Okano, Yutaka; Tojo, Takeshi.

In: Japanese Journal of Clinical Immunology, Vol. 17, No. 5, 1994, p. 547-551.

Research output: Contribution to journalArticle

@article{1fe5eb84aafb4393bfea2ffe7ef7d507,
title = "Reactivity against the epitope region 4 (ER 4) on the DNA topoisomerase I molecule as a new predictor for progressive restrictive pulmonary function abnormality in patients with systemic sclerosis",
abstract = "Our previous studies showed that serum anti-DNA topoisomerase I (topo I) antibody is associated with pulmonary interstitial fibrosis and restrictive pulmonary function abnormality in patients with systemic sclerosis (SSc). We also demonstrated that at least four epitopes exist on the topo I molecule, and a region from amino acid residues 658-700 of the topo I molecule is referred to as epitope region 4 (ER 4). In this study, we examined the reactivity against ER 4 in sera from 28 anti-topo I antibody positive patients with SSc by immunoblotting. We then clarified the clinical significance of this reactivity against ER 4 in terms of the progressive restrictive pulmonary function abnormality. The reactivity against ER 4 was found to be positive in 15 patients (ER 4 +) and negative in 13 patients (ER 4 —). Differences in gender, mean age at onset, and mean observation period were not significant among these groups. Restrictive pulmonary function abnormality defined as results of percent vital capacity ({\%}VC) less than 80{\%} was found in 12 ER 4+patients and 8 ER 4-patients, although this difference was not significant. However, when progressive restrictive pulmonary function abnormality is defined as both {\%}VC less than 80{\%} and 10{\%} reduction during their observation period, this abnormality was found exclusively in 9 ER 4 + patients. This difference was significant (p < 0.01). Moreover, this progressive abnormality was found in spite of therapy such as prednisolone and D-penicillamine. These results indicated that the reactivity against ER 4 is a useful predictor for the progressive restrictive pulmonary function abnormality in patients with SSc.",
keywords = "anti-DNA topoisomerase I antibody, epitope, restrictive pulmonary function abnormality, scleroderma, systemic sclerosis",
author = "Junichi Kaburaki and Masataka Kuwana and Yasuo Ikeda and Michito Hirakata and Yutaka Okano and Takeshi Tojo",
year = "1994",
doi = "10.2177/jsci.17.547",
language = "English",
volume = "17",
pages = "547--551",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Reactivity against the epitope region 4 (ER 4) on the DNA topoisomerase I molecule as a new predictor for progressive restrictive pulmonary function abnormality in patients with systemic sclerosis

AU - Kaburaki, Junichi

AU - Kuwana, Masataka

AU - Ikeda, Yasuo

AU - Hirakata, Michito

AU - Okano, Yutaka

AU - Tojo, Takeshi

PY - 1994

Y1 - 1994

N2 - Our previous studies showed that serum anti-DNA topoisomerase I (topo I) antibody is associated with pulmonary interstitial fibrosis and restrictive pulmonary function abnormality in patients with systemic sclerosis (SSc). We also demonstrated that at least four epitopes exist on the topo I molecule, and a region from amino acid residues 658-700 of the topo I molecule is referred to as epitope region 4 (ER 4). In this study, we examined the reactivity against ER 4 in sera from 28 anti-topo I antibody positive patients with SSc by immunoblotting. We then clarified the clinical significance of this reactivity against ER 4 in terms of the progressive restrictive pulmonary function abnormality. The reactivity against ER 4 was found to be positive in 15 patients (ER 4 +) and negative in 13 patients (ER 4 —). Differences in gender, mean age at onset, and mean observation period were not significant among these groups. Restrictive pulmonary function abnormality defined as results of percent vital capacity (%VC) less than 80% was found in 12 ER 4+patients and 8 ER 4-patients, although this difference was not significant. However, when progressive restrictive pulmonary function abnormality is defined as both %VC less than 80% and 10% reduction during their observation period, this abnormality was found exclusively in 9 ER 4 + patients. This difference was significant (p < 0.01). Moreover, this progressive abnormality was found in spite of therapy such as prednisolone and D-penicillamine. These results indicated that the reactivity against ER 4 is a useful predictor for the progressive restrictive pulmonary function abnormality in patients with SSc.

AB - Our previous studies showed that serum anti-DNA topoisomerase I (topo I) antibody is associated with pulmonary interstitial fibrosis and restrictive pulmonary function abnormality in patients with systemic sclerosis (SSc). We also demonstrated that at least four epitopes exist on the topo I molecule, and a region from amino acid residues 658-700 of the topo I molecule is referred to as epitope region 4 (ER 4). In this study, we examined the reactivity against ER 4 in sera from 28 anti-topo I antibody positive patients with SSc by immunoblotting. We then clarified the clinical significance of this reactivity against ER 4 in terms of the progressive restrictive pulmonary function abnormality. The reactivity against ER 4 was found to be positive in 15 patients (ER 4 +) and negative in 13 patients (ER 4 —). Differences in gender, mean age at onset, and mean observation period were not significant among these groups. Restrictive pulmonary function abnormality defined as results of percent vital capacity (%VC) less than 80% was found in 12 ER 4+patients and 8 ER 4-patients, although this difference was not significant. However, when progressive restrictive pulmonary function abnormality is defined as both %VC less than 80% and 10% reduction during their observation period, this abnormality was found exclusively in 9 ER 4 + patients. This difference was significant (p < 0.01). Moreover, this progressive abnormality was found in spite of therapy such as prednisolone and D-penicillamine. These results indicated that the reactivity against ER 4 is a useful predictor for the progressive restrictive pulmonary function abnormality in patients with SSc.

KW - anti-DNA topoisomerase I antibody

KW - epitope

KW - restrictive pulmonary function abnormality

KW - scleroderma

KW - systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85007961556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007961556&partnerID=8YFLogxK

U2 - 10.2177/jsci.17.547

DO - 10.2177/jsci.17.547

M3 - Article

AN - SCOPUS:85007961556

VL - 17

SP - 547

EP - 551

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 5

ER -